Acorai, a Swedish developer and manufacturer of innovative devices for heart failure management, announced the closing of a $4.5M investment from the EIC Fund, Taiwan Medical University, and private investors. The capital will be used to complete Acorai’s clinical studies and prepare for regulatory submissions in the US and Europe.
Patient enrolment for Acorai’s flagship clinical study, the CAPTURE-HF study, has been completed successfully, with over 1600 patients across 20 hospitals and 6 countries. With its FDA Breakthrough Device Designation in place and working closely with the FDA through the TAP Pilot, Acorai targets regulatory submissions and commercial launch by 2026.
Related: Sirona Medical raises $42M in Series C financing for radiology software
With an additional $6M provisioned from the EIC Fund for future equity financing, Acorai is preparing to raise additional capital in 2025 to fund further clinical validation, regulatory approvals and early commercialisation.
Acorai CEO Filip Peters commented, “We are happy to welcome the EIC Fund as an investor in Acorai and look forward to working closely with the fund as one of Europe’s leading deep tech investors. Acorai is at a transformative point and has built a solid foundation to become a world leader in non-invasive cardiac care. With more than $6M in additional capital provisioned from the EIC Fund to Acorai’s future funding rounds, this investment will allow Acorai to scale up its clinical and regulatory efforts to reach the market. This represents another important step toward bringing our solution to the market, with the potential to impact over 60 million heart failure patients worldwide positively.”
